Previous Close | 0.9220 |
Open | 0.9900 |
Bid | 0.0000 x 1200 |
Ask | 0.0000 x 800 |
Day's Range | 0.9500 - 1.0000 |
52 Week Range | 0.9000 - 2.5000 |
Volume | |
Avg. Volume | 90,066 |
Market Cap | 83.886M |
Beta (5Y Monthly) | 1.84 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4790 |
Earnings Date | Mar 15, 2022 - Mar 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 13, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the first quarter ended March 31, 2022.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., May 06, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company’s 2022 first quarter financial and operational results.
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., April 28, 2022--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company’s lead compound, maveropepimut-S (MVP-S), will be showcased in two presentations in breast and ovarian cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held in-person and virtua